Skip to content

Efficacy of a novel cream with antiedema function in the treatment of cellulite

Efficacy of a novel hypertonic draining cream for cellulite reduction: a Clinical and instrumental (Antera 3D) assessment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN15111614
Enrollment
20
Registered
2017-07-13
Start date
2016-11-01
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gynoid lipodystrophy (Cellulite) Skin and Connective Tissue Diseases Gynoid lipodystrophy (Cellulite)

Interventions

Participants are given an hypertonic topical product with draining action (HTC cream) that contains NaCl 13%, escine, caffeine and beta-sytosterol. They are asked to apply it once daily on their thigh

Sponsors

Difa Cooper
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Women aged 18-65 years 2. Have grade II-IV gynoid lipodystrophy

Exclusion criteria

Exclusion criteria: 1. Previous treatment (within 2 months of the study period) for cellulite (topical or oral) 2. Positive history for lower limbs venous or lymphatic insufficiency 3. Pregnancy or breast feeding 4. Positive history of allergic contact dermatitis to any of the component of the cream

Design outcomes

Primary

MeasureTime frame
1. Thigh circumferential is measured using a flexible measuring ruler with the participant in standing position and performing the measurement up to 25 cm from the superior pole of the patella at baseline, one and two months 2. Computer-analysis of skin profilometry of a pre-specified target area (in general in the zone above the trochanteric eminence or gluteal zone) evaluated by means of Antera 3D CS (Miravex, Dublin, Ireland) at baseline and two months

Secondary

MeasureTime frame
Cellulite (skin appearance) are measured using the orange peel severity score (0 to 5) before and after the pinch test at baseline, one and two months.

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 25, 2026